A trial of therapeutic doses of B6 (administration of 100 mg or more of pyridoxine) is indicated in infants / children with intractable seizures unresponsive to standard anti-epileptic drug (AED) treatment (24, 25, 26, 35, 36, 37, 38). Intravenous or intramuscular administration is recommended in infants with ongoing seizures or status epilepticus, in order to achieve immediate resolution of seizures and clinical seizures generally cease over several minutes to hours (29). If responsive, oral maintenance dose of 2-500mg/day PO (15-18mg/kg/day optimally and sometimes as high as 680mg initially and 200 mg/day subsequently) has to be followed indefinitely (33, 35). Clinical seizures generally cease over several minutes to hours. Recommended daily allowance (RDA) for pyridoxine is 0.5 mg for infants and 2.0 mg for adults or 50-100 mg of pyridoxine per day (38, 39, 40) with dosage adjustment for age, intercurrent illnesses and to allow greatest intellectual performance but not exceeding 500 mg/day (27, 28, 36, 38, 41). The chance to identify specificity is lost if pyridoxine is given together with or after, many anticonvulsant drugs (27). Daily supplementation with pharmacologic doses of pyridoxine is the accepted treatment for this disorder.